Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

Antonio J. Vallejo-Vaz; Rana Fayyad; S. Matthijs Boekholdt; G. Kees Hovingh; John J. Kastelein; Shari Melamed; Philip Barter; David D. Waters; Kausik K. Ray

doi:10.1161/CIRCULATIONAHA.117.032318

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

Antonio J. Vallejo-Vaz
, Rana Fayyad
, S. Matthijs Boekholdt
, G. Kees Hovingh
, John J. Kastelein
, Shari Melamed
, Philip Barter
, David D. Waters
, Kausik K. Ray

Research output: Contribution to journal › Article › Academic › peer-review

21 Downloads (Pure)

Abstract

BACKGROUND: Mendelian randomization data suggest that the genetic determinants of lifetime higher triglyceride-rich lipoprotein-cholesterol (TRL-C) are causally related to cardiovascular disease and therefore a potential therapeutic target. The relevance of TRL-C among patients receiving statins is unknown. We assessed the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial (Treating to New Targets).

Original language	English
Pages (from-to)	770-781
Journal	Circulation
Volume	138
Issue number	8
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.117.032318
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1161/CIRCULATIONAHA.117.032318

Triglyceride-rich-lipoprotein-cholesterol-and-risk-of-cardiovascular-events-among-patients-receiving-statin-therapy-in-t.pdfFinal published version, 1.04 MBLicence: Taverne

Cite this

@article{74d43ffa6f7a445aa7f604b3187cbef8,

title = "Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial",

abstract = "BACKGROUND: Mendelian randomization data suggest that the genetic determinants of lifetime higher triglyceride-rich lipoprotein-cholesterol (TRL-C) are causally related to cardiovascular disease and therefore a potential therapeutic target. The relevance of TRL-C among patients receiving statins is unknown. We assessed the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial (Treating to New Targets).",

author = "Vallejo-Vaz, \{Antonio J.\} and Rana Fayyad and Boekholdt, \{S. Matthijs\} and Hovingh, \{G. Kees\} and Kastelein, \{John J.\} and Shari Melamed and Philip Barter and Waters, \{David D.\} and Ray, \{Kausik K.\}",

year = "2018",

doi = "10.1161/CIRCULATIONAHA.117.032318",

language = "English",

volume = "138",

pages = "770--781",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

TY - JOUR

T1 - Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

AU - Vallejo-Vaz, Antonio J.

AU - Fayyad, Rana

AU - Boekholdt, S. Matthijs

AU - Hovingh, G. Kees

AU - Kastelein, John J.

AU - Melamed, Shari

AU - Barter, Philip

AU - Waters, David D.

AU - Ray, Kausik K.

PY - 2018

Y1 - 2018

N2 - BACKGROUND: Mendelian randomization data suggest that the genetic determinants of lifetime higher triglyceride-rich lipoprotein-cholesterol (TRL-C) are causally related to cardiovascular disease and therefore a potential therapeutic target. The relevance of TRL-C among patients receiving statins is unknown. We assessed the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial (Treating to New Targets).

AB - BACKGROUND: Mendelian randomization data suggest that the genetic determinants of lifetime higher triglyceride-rich lipoprotein-cholesterol (TRL-C) are causally related to cardiovascular disease and therefore a potential therapeutic target. The relevance of TRL-C among patients receiving statins is unknown. We assessed the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial (Treating to New Targets).

UR - https://www.scopus.com/pages/publications/85055023130

UR - https://www.ncbi.nlm.nih.gov/pubmed/29618599

U2 - 10.1161/CIRCULATIONAHA.117.032318

DO - 10.1161/CIRCULATIONAHA.117.032318

M3 - Article

C2 - 29618599

SN - 0009-7322

VL - 138

SP - 770

EP - 781

JO - Circulation

JF - Circulation

IS - 8

ER -

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this